Zobrazeno 1 - 10
of 53
pro vyhledávání: '"B. Devens"'
Autor:
Yasutomo Fujii, Takahisa Noto, Yasuyuki Higashi, Steven J. Chapin, Margaret Neighbors, Yuka Kawato, Shinsuke Oshima, B. Devens, Masashi Maeda, Sridhar Viswanathan, Susumu Tsujimoto, Jun Hirose, Hidehiko Fukahori, Fujiko Takamura, Erik E. Karrer, Koji Nakamura, Takanori Marui
Publikováno v:
Transplantation. 100(12)
Background Blockade of CD28-mediated T cell costimulation by a modified cytotoxic T lymphocyte-associated antigen 4 (CTLA4-Ig), belatacept, is a clinically effective immunosuppressive therapy for the prevention of renal allograft rejection. Use of be
Autor:
T. Barnett, J. Teare, Glenn F. Pierce, Liang Tang, M. Parmathi, K. Landskroner, J. Strauss, C. Pan, J. E. Murphy, J. Newgren, M. Fournel, Haiyan Jiang, B. Devens, J. Severs, P. Esmon, K. Konstantinov, B. Mei, H. Tjandra
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:P-T
Autor:
Denise J. Lo, F. Leopardi, Elizabeth Strobert, Douglas J. Anderson, Steven J. Chapin, Erik E. Karrer, Allan D. Kirk, Mingqing Song, B. Devens
Publikováno v:
Transplantation. 98:288
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 272(1)
Leflunomide is a novel and effective immunosuppressant that holds promise as a therapeutic agent, but the mechanism of action is unknown. Here we provide evidence that leflunomide is a general cytostatic agent for a wide range of cells. The IC50 for
Publikováno v:
Transplantation. 28:389-395
Publikováno v:
European Journal of Immunology. 8:17-22
This report describes model systems which show low primary in vitro syngeneic cytotoxic responses to a Moloney-induced YAC tumor (syngeneic in A mice) and a Rauscher-induced RBL5 tumor (syngeneic in C57BL/6 mice) and examines different approaches to
Publikováno v:
The Journal of Immunology. 125:988-994
Publikováno v:
Immunobiology. 159:432-443
The ability of the in vitro propagated syngeneic tumor YAC-1 and the allogeneic tumor RBL5 to stimulate cytotoxic cells in A mice, was in correlation with the ability of these tumors to impose in vivo resistance to the viable YAC cells. Similarly, th
Publikováno v:
Cellular Immunology. 44:442-453
YAC tumor, a Moloney virus-induced lymphoma of A mice, considerably changes its immunogenic properties following cultivation for 12 to 14 hr in vitro. The cultivated tumor, designated YAC-1, generates anti-YAC and anti-YAC-1 reactive cells, while the
Publikováno v:
Israel journal of medical sciences. 16(7)
YAC, a Moloney-virus-induced tumor of A mice, caused an inhibition of specific immunologic responses in A and C57BL/6 mice, which was mediated by suppressor cells. In contrast, YAC-1, the in vitro-carried tumor derived from cultivated YAC cells, stim